Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INBX NASDAQ:KYMR NASDAQ:PTGX NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBXInhibrx Biosciences$117.95+8.6%$86.13$10.84▼$155.29$1.59B3.88679,269 shs880,051 shsKYMRKymera Therapeutics$85.59+2.4%$83.69$28.06▼$103.00$6.87B2.06507,932 shs408,524 shsPTGXProtagonist Therapeutics$103.88+3.9%$100.30$43.20▼$107.84$6.43B1.89633,554 shs518,199 shsQGENQiagen$32.74-2.9%$39.64$32.53▼$57.81$6.94B0.642.30 million shs4.03 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBXInhibrx Biosciences+8.56%-16.84%+52.27%+43.65%+945.66%KYMRKymera Therapeutics+2.44%-0.78%-3.32%+1.87%+174.86%PTGXProtagonist Therapeutics+3.93%-0.09%+6.47%+26.79%+134.65%QGENQiagen-2.77%-4.99%-21.94%-35.69%-26.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBXInhibrx Biosciences$117.95+8.6%$86.13$10.84▼$155.29$1.59B3.88679,269 shs880,051 shsKYMRKymera Therapeutics$85.59+2.4%$83.69$28.06▼$103.00$6.87B2.06507,932 shs408,524 shsPTGXProtagonist Therapeutics$103.88+3.9%$100.30$43.20▼$107.84$6.43B1.89633,554 shs518,199 shsQGENQiagen$32.74-2.9%$39.64$32.53▼$57.81$6.94B0.642.30 million shs4.03 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBXInhibrx Biosciences+8.56%-16.84%+52.27%+43.65%+945.66%KYMRKymera Therapeutics+2.44%-0.78%-3.32%+1.87%+174.86%PTGXProtagonist Therapeutics+3.93%-0.09%+6.47%+26.79%+134.65%QGENQiagen-2.77%-4.99%-21.94%-35.69%-26.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBXInhibrx Biosciences 2.33Hold$150.0027.17% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1037.98% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.699.45% UpsideQGENQiagen 2.50Moderate Buy$46.3841.68% UpsideCurrent Analyst Ratings BreakdownLatest INBX, KYMR, QGEN, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBXInhibrx Biosciences$1.30M1,325.58N/AN/A$0.55 per share214.45KYMRKymera Therapeutics$39.21M179.56N/AN/A$18.72 per share4.57PTGXProtagonist Therapeutics$46.02M145.17N/AN/A$10.19 per share10.19QGENQiagen$2.09B3.23$3.31 per share9.90$16.17 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBXInhibrx Biosciences-$140.05M-$9.04N/AN/AN/AN/A-269.56%-71.94%N/AKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/APTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%N/AQGENQiagen$424.88M$1.9117.1012.173.3519.16%14.40%8.40%N/ALatest INBX, KYMR, QGEN, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/A2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AQGENQiagen$0.260.79%N/A13.61%N/ALatest INBX, KYMR, QGEN, and PTGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBXInhibrx Biosciences12.583.933.93KYMRKymera TherapeuticsN/A10.8110.81PTGXProtagonist TherapeuticsN/A17.7617.76QGENQiagen0.493.213.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBXInhibrx Biosciences82.46%KYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipINBXInhibrx Biosciences17.09%KYMRKymera Therapeutics15.98%PTGXProtagonist Therapeutics5.19%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBXInhibrx Biosciences16614.61 million12.11 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableINBX, KYMR, QGEN, and PTGX HeadlinesRecent News About These CompaniesQIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 MillionMay 13 at 5:34 PM | businesswire.comQiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13 at 1:01 AM | seekingalpha.comQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingMay 12 at 2:00 AM | businesswire.comDeciphering Qiagen (QGEN) International Revenue TrendsMay 11 at 10:16 AM | zacks.comLost Money on Qiagen N.V. (QGEN)? Contact Levi & Korsinsky to Protect Your RightsMay 10, 2026 | newsfilecorp.comNQiagen (NYSE:QGEN) Hits New 1-Year Low - Time to Sell?May 10, 2026 | americanbankingnews.comQiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing - SlideshowMay 9, 2026 | seekingalpha.comM&T Bank Corp Takes $2.19 Million Position in Qiagen N.V. $QGENMay 9, 2026 | marketbeat.comQiagen (NYSE:QGEN) Valuation Check After Extended Share Price WeaknessMay 8, 2026 | finance.yahoo.comQiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing TranscriptMay 8, 2026 | seekingalpha.comQiagen (QGEN) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comQiagen (NYSE:QGEN) Sets New 12-Month Low - Should You Sell?May 8, 2026 | marketbeat.comQiagen Files U.S. GAAP Quarterly Report for First Quarter 2026May 8, 2026 | tipranks.comQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB TestingMay 7, 2026 | finance.yahoo.comQGEN SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Qiagen for Possible Securities Law ViolationsMay 7, 2026 | globenewswire.comQiagen: Q1 Earnings SnapshotMay 6, 2026 | stamfordadvocate.comSQiagen (QGEN) Q1 Earnings and Revenues Lag EstimatesMay 6, 2026 | zacks.comQiagen (QGEN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 6, 2026 | zacks.comLevi & Korsinsky Investigates Qiagen N.V. (QGEN) Over Potential Securities Fraud AllegationsMay 6, 2026 | newsfilecorp.comNQGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law FirmMay 6, 2026 | globenewswire.comQIAGEN Reports Full Results for Q1 2026May 6, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINBX, KYMR, QGEN, and PTGX Company DescriptionsInhibrx Biosciences NASDAQ:INBX$117.95 +9.30 (+8.56%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$115.98 -1.98 (-1.67%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Kymera Therapeutics NASDAQ:KYMR$85.59 +2.04 (+2.44%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$85.64 +0.05 (+0.05%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$103.88 +3.93 (+3.93%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$104.17 +0.29 (+0.28%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Qiagen NYSE:QGEN$32.74 -0.96 (-2.86%) Closing price 05/13/2026 03:59 PM EasternExtended Trading$33.15 +0.41 (+1.26%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
